脂龙活血通瘀胶囊治疗急性脑梗死的系统评价与Meta分析
该系统评价与Meta分析纳入7项随机对照试验共571例急性脑梗死患者,评估脂龙活血通瘀胶囊(ZL)联合常规治疗的疗效。结果显示,与单用常规治疗相比,联合ZL可显著提高临床有效率(RR=1.20,95%CI:1.12-1.29,p<0.00001),降低NIHSS评分(MD=-2.60,95%CI:-3.41至-1.79,p<0.00001),改善Barthel指数(MD=-9.75,95%CI:7.15-12.36,p<0.00001)及改良Rankin量表评分(MD=-0.57,95%CI:-0.84至-0.30,p<0.00001),且未报告不良事件。结论认为ZL联合常规治疗可改善ACI患者短期结局,但证据质量中至低,仍需高质量长期随访试验验证。
要点
- ZL联合常规治疗可提高ACI患者临床有效率(RR=1.20)。
- 联合治疗可降低NIHSS评分(MD=-2.60)并改善BI与MRS。
- 纳入研究未报告不良事件,但证据质量中至低。
核心结论
- ZL联合常规治疗可改善急性脑梗死患者的短期结局,可作为常规治疗的辅助选择。
- 受纳入试验局限性影响,仍需高质量、长随访临床试验进一步评估ZL的有效性与安全性。
研究设计与样本
- 纳入7项随机对照试验,共571例合格患者。
- 采用Cochrane手册进行方法学质量评价,Review Manager 5.3进行数据分析。
主要发现
- 与单用常规治疗相比,ZL联合常规治疗显著提高临床有效率(RR=1.20,95%CI:1.12-1.29,p<0.00001)。
- 联合治疗显著降低NIHSS评分(MD=-2.60,95%CI:-3.41至-1.79,p<0.00001)。
- 联合治疗显著改善Barthel指数(MD=-9.75,95%CI:7.15-12.36,p<0.00001)。
- 联合治疗显著降低改良Rankin量表评分(MD=-0.57,95%CI:-0.84至-0.30,p<0.00001)。
- 纳入研究未报告不良事件,大多数结果稳健,证据质量中至低。
关键数值与推荐
- 主要结局为临床有效率(CER)。
- 次要结局包括美国国立卫生研究院卒中量表(NIHSS)、Barthel指数(BI)和改良Rankin量表(MRS)。
临床怎么用
- 在急性脑梗死常规治疗基础上,可考虑联合ZL以改善短期神经功能与日常活动能力。
- 应用时需结合患者具体情况,并关注证据质量中至低的局限性。
局限性
- 纳入临床试验存在局限性,证据质量从中等到低。
- 缺乏长期随访数据,ZL的远期疗效与安全性尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Zhilong Huoxue Tongyu capsule (ZL) is a Chinese patent medicine and used for the treatment of acute cerebral infarction (ACI) and its clinical application has gradually been widely recognized in China. However, the effects of ZL for patients with ACI have never been systematically evaluated. PURPOSE: A systematic review and meta-analysis was performed to evaluate the efficacy of ZL in ACI. STUDY DESIGN: A systematic review and meta-analysis of randomized clinical trials (RCTs). MATERIALS AND METHODS: A systematic review and meta-analysis were performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The comprehensive literature search was accomplished in 6 electronic databases to find relevant randomized controlled trials from their inception until October 31, 2020. The Cochrane Handbook for Systematic Reviews of Interventions was used for methodological quality and independent evaluation. Review Manager 5.3 was used to analyze all the data obtained. The Clinical Effective Rate (CER) was the primary outcome, and the National Institutes of Health Stroke Score (NIHSS), Barthel Index (BI), and Modified Rankin Scale (MRS) were the secondary outcomes. RESULTS: Seven clinical studies recruiting 571 eligible patients were included in this meta-analysis. The results of meta-analysis suggested that compared with conventional treatment alone, ZL combined with conventional treatment significantly improved CER (RR = 1.20, 95% CI: 1.12-1.29, p < 0.00001), decrease National Institutes of Health Stroke Scale Score (NIHSS) (MD = -2.60, 95% CI: -3.41-1.79, p < 0.00001), Barthel Index (BI) (MD = -9.75, 95% CI: 7.15-12.36, p < 0.00001) and Modified Rankin Scale (MRS) (MD = -0.57, 95% CI: -0.84-0.30, p < 0.00001). There were no reported adverse events in the studies. Most results were robust and the quality of evidence was from moderate to low. CONCLUSION: ZL combined with conventional treatment can improve the short-term outcomes of ACI patients, indicating ZL is a promising treatment choice for ACI and may be used as adjunctive treatment to the conventional treatment of ACI. However, due to the limitations of included clinical trials, high-quality clinical trials with longer follow-ups are still needed to further assess the effectiveness and safety of ZL for ACI patients.
引用
- Liu M, Pu Y, Gu J, et al. Evaluation of Zhilong Huoxue Tongyu capsule in the treatment of acute cerebral infarction: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2021. PMID: 33940333. doi:10.1016/j.phymed.2021.153566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。